<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066373</url>
  </required_header>
  <id_info>
    <org_study_id>EDP1815-104</org_study_id>
    <nct_id>NCT05066373</nct_id>
  </id_info>
  <brief_title>Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms</brief_title>
  <official_title>A Phase 1, Single Centre, Two-part, Open Label, Crossover Study in Healthy Volunteers Using Scintigraphy to Evaluate the Gastrointestinal Behaviour of EDP1815 Oral Dosage Forms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evelo Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evelo Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to find out how different types of capsules or tablets containing EDP1815 move&#xD;
      through the GI tract and release the drug after being swallowed. The capsules and tablets&#xD;
      also contain a very small dose of a commonly used radioactive label called technetium-99m&#xD;
      which is released in the GI tract to be seen on pictures taken by a scanner (gamma&#xD;
      scintigraphy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I single centre, open-label, 2-part, crossover, gamma scintigraphy study to&#xD;
      investigate the gastrointestinal transit and disintegration kinetics of capsule and tablet&#xD;
      formulations of EDP1815 (which contains a specific pure strain of Prevotella histicola, a&#xD;
      natural human commensal organism).&#xD;
&#xD;
      In Part 1, up to 12 healthy male volunteers will receive single doses of EDP1815 administered&#xD;
      either as capsules or tablets in 4 treatment periods separated by up to 21 days. Each capsule&#xD;
      or tablet will contain the radio-isotope technetium-99m complexed to DTPA; 99mTc-DTPA, does&#xD;
      not enter the systemic circulation and is routinely used for investigations of this type.&#xD;
      Imaging via gamma scintigraphy will be used to assess the gut transit time and disintegration&#xD;
      location/rate of the capsules/tablets. In three of the periods the drug will be given fasted,&#xD;
      and in the final period the effect of food will be assessed.&#xD;
&#xD;
      The data generated in Part 1 will be assessed prior to progressing to Part 2 to select&#xD;
      formulations and doses to be studied. Part 2 will include gamma scintigraphy in up to 12&#xD;
      healthy volunteers receiving single doses or EDP1815 capsules or tablets over up to 4&#xD;
      treatment periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to onset of radiolabel release</measure>
    <time_frame>up to 12 hours</time_frame>
    <description>The time to onset of disintegration/release for each EDP1815 formulation will be measured by using the time of onset of radiolabel release</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Site of onset of radiolabel release</measure>
    <time_frame>up to 12 hours</time_frame>
    <description>The site of onset of disintegration/release for each EDP1815 formulation will be determined by using the time to onset of radiolabel release</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying time</measure>
    <time_frame>up to 12 hours</time_frame>
    <description>Gastrointestinal transit parameters will be measured using the gastric emptying time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small intestinal transit time</measure>
    <time_frame>up to 12 hours</time_frame>
    <description>Gastrointestinal transit parameters will be measured using the small intestinal transit time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colon arrival time</measure>
    <time_frame>up to 12 hours</time_frame>
    <description>Gastrointestinal transit parameters will be measured using the colon arrival time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% release (T50)</measure>
    <time_frame>up to 12 hours</time_frame>
    <description>The radiolabel release kinetics of each EDP1815 formulation will be measured using the time to 50% release (T50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 90% release (T90)</measure>
    <time_frame>up to 12 hours</time_frame>
    <description>The radiolabel release kinetics of each EDP1815 formulation will be measured using the time to 90% release (T90)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Disintegration</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>EDP1815 capsule A (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1 period 1, 12 healthy volunteers will receive a single dose of EDP1815 capsule A, dosed in the fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP1815 capsule B (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1 period 2, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP1815 tablet (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1 period 3, 12 healthy volunteers will receive a single dose of EDP1815 tablet, dosed in the fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP1815 capsule B (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1 period 4, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP1815 capsule A</intervention_name>
    <description>EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA</description>
    <arm_group_label>EDP1815 capsule A (fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP1815 capsule B</intervention_name>
    <description>EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA</description>
    <arm_group_label>EDP1815 capsule B (fasted)</arm_group_label>
    <arm_group_label>EDP1815 capsule B (fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP1815 tablet</intervention_name>
    <description>EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA</description>
    <arm_group_label>EDP1815 tablet (fasted)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. Body weight ≥50 kg and BMI 18-30 kg/m²&#xD;
&#xD;
          3. Healthy&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of any medical condition or abnormal laboratory test findings at&#xD;
             screening that could affect the study conduct/results, or make the participant&#xD;
             unlikely to fully complete the study or potentially adversely affect their safety due&#xD;
             to taking part.&#xD;
&#xD;
          2. History of non-self-limiting gastrointestinal disorders, or currently suffering from&#xD;
             disease known to impact gastric emptying, e.g. migraine, Type 1 or Type 2 diabetes&#xD;
             mellitus.&#xD;
&#xD;
          3. Any contraindication to gamma scintigraphy.&#xD;
&#xD;
          4. Any non-removable metal objects such as metal plates, screws in the chest or abdominal&#xD;
             area.&#xD;
&#xD;
          5. Total radiation dosimetry value which contraindicates participation.&#xD;
&#xD;
          6. Use of prescribed medication within 14 days prior to first dose which could interfere&#xD;
             with the study procedures or affect gastric emptying and/or gut transit.&#xD;
&#xD;
          7. Use of over-the-counter (OTC) medication, including vitamins, pro and prebiotics and&#xD;
             natural or herbal remedies, within 48 hours prior to first dose.&#xD;
&#xD;
          8. History of alcohol or other substance abuse.&#xD;
&#xD;
          9. Current smoker or recently discontinued smoking (less than 3 months).&#xD;
&#xD;
         10. History of allergy to any component of the dosage form or any other allergy which&#xD;
             contraindicates participation.&#xD;
&#xD;
         11. Vegetarian or vegan.&#xD;
&#xD;
         12. Participation in another clinical study with an investigational drug within the prior&#xD;
             12 weeks, or more than three other clinical studies in the prior 12 month period.&#xD;
&#xD;
         13. Participants unwilling to comply with contraception requirements from first dose until&#xD;
             90 days (use of condom/spermicide in addition to use of protocol-specified highly&#xD;
             effective contraception by female partners who could become pregnant)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Stevens, BPharm PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BDD Pharma Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise Dyce</last_name>
    <phone>0141 552 8791</phone>
    <email>louise.dyce@bddpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BDD Pharma Ltd</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

